On Monday, Catalyst Pharmaceuticals got an upgrade for its IBD SmartSelect Composite Rating from 92 to 96.
The upgrade means the stock is now outperforming 96% of all other stocks in terms of key performance metrics and technical strength. History shows the top market performers tend to have a 95 or higher score as they launch their major climbs.
Catalyst Pharmaceuticals is currently forming a consolidation, with a 17.50 entry. Look for the stock to break out in volume at least 40% above average.
Looking For The Best Stocks To Buy And Watch? Start Here
The stock earns an 82 EPS Rating, meaning its recent quarterly and annual earnings growth is outpacing 82% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
In Q1, the company posted -7% earnings growth. Top line growth fell to 15%, down from 82% in the previous quarter.
Catalyst Pharmaceuticals holds the No. 7 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Halozyme Therapeutics and Sarepta Therapeutics are among the top 5 highly-rated stocks within the group.
